Bibliography
- Ligaray KPL, Isley WL. Diabetes mellitus, type 2. Available from: http://emedicine.medscape.com/article/117853-overview [Accessed 24 September 2013]
- Stratton IM, Adler AI, Matthews DR, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
- Selvin E, Ning Y, Steffes MW, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 2011;60:298-305
- FDA announces new recommendations on evaluating cardiovascular risk in drugs intended to treat type 2 diabetes. Available from: http://www.fda.gov/Newsevents/Newsroom/PressAnnouncements/2008/ucm116994.htm [Accessed 27 November 2013]
- Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
- Nissen SE, Wolski K. Rosiglitazone revisited: and updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201
- Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-18
- European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1 [Accessed 27 November 2013]
- FDA Guidance for Industry. Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetes therapies to treat type 2 diabetes. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf [Accessed 11 December 2013]
- Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27
- Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Eng J Med 2013;369:1317-26
- White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:688-73
- White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35
- Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-inhibitors and cardiovascular outcomes: a meta-analysis of randomized clinical trials. Available from: http://www.asceptasm.com/wp-content/uploads/2013/06/ASCEPT-abstracts-202-315.pdf [Accessed 26 February 2014]
- Green JB, Bethel MA, Paul SK, et al. Rational, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013;166:983-9. e7
- Johansen OE, Neubacher D, Von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis or a phase 3 programme. Cardiovasc Diabetol 2012, doi:10.1186/1475-2840-11-3
- CAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. Available from: http://clinicaltrials.gov/ct2/show/NCT01243424?term=linagliptin&rank=23 [Accessed 28 November 2013]
- Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:112-20